At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
|Videos|January 18, 2018
Adding TTFields to Chemotherapy to Improves Survival in Glioblastoma
Author(s)Roger Stupp, MD
Roger Stupp, MD, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma.
Advertisement
Advertisement
Related to this article
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5